FDA Advisory Committees
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Advisory Committees
US CDC influenza official says that capacity is not an issue, since the system is already scaled for a pandemic, but a key will be availability of testing to distinguish the viruses.
Lilly included progression-free survival 2 as an exploratory endpoint in RELAY on the advice of the European Medicines Agency and says study results show continuing benefit from first-line ramucirumab even after progression; FDA says endpoint is not valid for regulatory purposes and is subject to confounding.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.